Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)

Press release content from Business Wire. The AP news staff was not involved in its creation.

Related Keywords

Brussel ,Bruxelles Capitale ,Belgium ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Brussels ,Massachusetts ,Nagesh Mahanthappa ,Dunaway Young ,Ariane Lovell ,Rushmie Nofsinger ,Thomas Crawford ,Johns Hopkins University ,Scholar Rock Inc ,Linkedin ,International Congress On Neuromuscular Diseases ,Twitter ,Brussel Convention Centre ,Drug Administration ,Exchange Commission ,Topic Group ,European Medicines Agency ,International Congress ,Neuromuscular Diseases ,Founding Chief Executive Officer ,Abstract Number ,Poster Session ,Clive Booth ,Fast Track ,Orphan Drug ,Rare Pediatric Disease ,Priority Medicines ,Orphan Medicinal Product ,Scholar Rock ,Securities Act ,Private Securities Litigation Reform Act ,Quarterly Report ,Higher Functioning Individuals ,Spinal Muscular ,Business Wire ,Covid 19 ,Health ,Clinical Trials ,Sapphire ,Europe ,Congress ,Business ,